Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BNTX with free AI briefings, catalyst countdowns, and dilution alerts.

BNTX · BioNTech SE

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13.7B Cash on Hand
712.2mo Cash Runway
Follow BNTX by email Get an email when BNTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BNTX, unsubscribe in one click. Privacy

📣 What BNTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Gotistobart Non Small Cell Lung Cancer Phase 3 · NCT05671510 Active not recruiting
CAPOX Untreated, Unresectable, or Metastatic Colorectal Cancer Phase 2/3 · NCT07221357 Recruiting
Elfetabart Drozuntecan (DB-1311) Metastatic Castration-resistant Prostate Cancer Phase 3 · NCT07365995 Recruiting
Trastuzumab Pamirtecan (BNT323) Endometrial Cancer Phase 3 · NCT06340568 Recruiting
Nab-paclitaxel Metastatic Breast Cancer Phase 3 · NCT06018337 Active not recruiting
FOLFOX Untreated, Unresectable, or Metastatic Colorectal Cancer Phase 2/3 · NCT07221357 Recruiting
FOLFIRI Untreated, Unresectable, or Metastatic Colorectal Cancer Phase 2/3 · NCT07221357 Recruiting
Tozinameran COVID-19 Phase 3 · NCT07300839 Completed
Doxorubicin Endometrial Cancer Phase 3 · NCT06340568 Recruiting
HPV16 E6/7 mRNA Vaccine BNT113 Unresectable Head and Neck Squamous Cell Carcinoma Phase 2/3 · NCT04534205 Active not recruiting
Prednisolone Metastatic Castration-resistant Prostate Cancer Phase 3 · NCT07365995 Recruiting
Trastuzumab Emtansine HER2-positive Breast Cancer Phase 3 · NCT06265428 Active not recruiting
Eribulin Breast Neoplasms Phase 3 · NCT07173751 Recruiting
Pumitamig (BNT327) Extensive-stage Small-cell Lung Cancer Phase 3 · NCT06712355 Recruiting
Tecaginlimab (GEN1042) Non-CNS Tumor Phase 1/2 · NCT05491317 Terminated
Anti-OX40 Agonist Monoclonal Antibody GEN1055 Malignant Solid Tumor Phase 1/2 · NCT06391775 Terminated

Also used in these trials (approved or third-party drugs, not BNTX's own candidates): Pemetrexed Disodium, Capecitabine, Carboplatin, Nivolumab, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Durvalumab, Atezolizumab, Bevacizumab, Docetaxel Anhydrous, Etoposide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BNTX holds $13.7B in cash and short-term investments and burns about $57.7M/quarter from operations, an estimated runway of 712.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BNTX files for a raise →

👥 Who Owns BNTX

Insiders 16.2% Other 5%+ holders 40.5% Institutions (485 holders) 20.8% Public and other holders 22.5%
HolderTypeShares% of sharesAs of
ATHOS KG 5%+ holder (13G) 101,702,378 40.49% 2026-03-31
Ugur Sahin
Chief Executive Officer, 10% owner
Insider 39,218,111 15.61% 2026-10-08
Helmut Wolfgang Jeggle
Director
Insider 989,267 0.39% 2026-03-18
Sierk Poetting
Chief Operating Officer · +22,655 options
Insider 399,387 0.16% 2026-04-22
James Timothy Patrick Ryan
Chief Legal Officer and Chief Business O · +22,655 options
Insider 4,795 0.00% 2026-03-18
Ulrich Wandschneider
Director
Insider 1,927 0.00% 2026-03-18
Rudolf Staudigl
Director
Insider 400 0.00% 2026-03-18
Anja Morawietz
Director
Insider 240 0.00% 2026-03-18

Share count 251,204,366 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BNTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BNTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.